×
Back to Agenda
Session 3: Quality Considerations for Generic Drug-Device Combination Products (Continued)
Session Chair(s)
Susan Rosencrance, PhD
Acting Director, Office of Generic Drugs, CDER, FDA, United States
Session 3: Quality Considerations for Generic Drug-Device Combination Products (Continued)
Speaker(s)
Bing Cai, PhD
Division Director, OPQ, CDER , FDA, United States
Panelist
Intira Coowanitwong
Acting Quality Assessment Lead, OPQ, CDER, FDA, United States
Panelist
Gary Henniger
Sr Director, Global Device R&D Operations , Teva Pharmaceuticals, United States
Panelist
Steven Hertz, MBA, MS
Consumer Safety Officer, Office of Pharmaceutical Quality, CDER , FDA, United States
Panelist
James Jefferis Norman, PhD
Senior Chemist, OPF, OPQ, CDER, FDA, United States
Panelist
Brock Roughton
Acting Quality Assessment Lead, OPQ, CDER, FDA, United States
Panelist
Alan Stevens, MS
Global Head, Complex Devices and Drug Delivery Systems, AbbVie, United States
Panelist
Have an account?